Navigation Links
LeMaitre Vascular to Participate at Canaccord Adams Inaugural Cardiovascular Conference
Date:11/7/2007

BURLINGTON, Mass., Nov. 7 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), which develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease, is scheduled to participate at the Canaccord Adams inaugural Cardiovascular Conference on Tuesday, November 13, 2007, in New York City, NY at the Waldorf-Astoria Hotel.

David B. Roberts, President of LeMaitre Vascular, will provide an update on the company at 3:45 pm Eastern Standard Time.

A live audio webcast of the presentation will be available via the Internet at http://www.lemaitre.com/investor and will be available for replay for 30 days.

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures and markets medical devices and implants for the treatment of peripheral vascular disease. The Company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803. Additional information can be found at http://www.lemaitre.com.


'/>"/>
SOURCE LeMaitre Vascular, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. LeMaitre Vascular to Start Italian Sales Force
2. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
3. LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
4. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
5. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
6. Pot bellies linked to early signs of cardiovascular disease
7. Air pollution linked to cardiovascular risk indices in healthy young adults
8. Environmental stress probed in cardiovascular disease, diabetes
9. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
10. American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC)
11. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: